Boston Sunday Globe

Lawsuit threatens miscarriag­e care

Legal challenge puts abortion pill in jeopardy

- By Laura Ungar

Less than a year after losing her daughter Emilia at five days old, Jillian Phillips suffered a miscarriag­e.

It was Halloween weekend in 2016, and her doctor said she could wait for it to end naturally, have a surgical procedure, or take medication. She chose the medicine, passed the remains of her nine-week pregnancy at home, and buried them in a memorial garden, near some of Emilia’s ashes.

“Once I found out that the baby inside me was no longer viable, I didn’t want to just walk around carrying the emotional trauma of that,” said Phillips, a 41-year-old single mother of three from North Brookfield, Mass. “You just kind of want it finished. And the medication works pretty quickly.”

But the future of this common miscarriag­e treatment is in peril. The pill, mifepristo­ne, is used in abortions, making it a target.

Last month, a federal judge in Texas ruled to block mifepristo­ne’s approval by the Food and Drug Administra­tion. The Supreme Court later preserved access to the drug while the lawsuit winds through the courts, a long road that continues with arguments before an appeals court on May 17.

Doctors and patients fear mifepristo­ne could be pulled off the market when the legal wrangling ends. Already, they say, a chilling effect keeps some doctors from prescribin­g it.

A million US women a year suffer miscarriag­es, which occur in at least 15 percent of known pregnancie­s. Mifepristo­ne was approved in 2000 for early abortions but it is often used “off label” to treat early pregnancy loss or to speed up delivery when a fetus dies later in pregnancy. These uses are so common that US senators urged manufactur­er Danco to apply to the FDA to add miscarriag­e to the label of its drug, Mifeprex.

Denise Harle, an attorney for the group that filed the Texas lawsuit on behalf of antiaborti­on doctors and health care organizati­ons, said they aren't challengin­g uses of the drug beyond abortion. But legal experts say if it’s taken off the market for its approved use, it wouldn’t be available for pregnancy loss.

Dr. Kristyn Brandi said that would take away “the gold standard of miscarriag­e management," the two-drug combinatio­n of mifepristo­ne and misoprosto­l that helps empty the uterus and reduce the chance of infection.

“I offer it to every single patient whose miscarriag­e I manage,” said Brandi, an OB-GYN in Newark, New Jersey. “There will be a big impact if I am no longer able to use that medication.”

Brandi said medication speeds up the miscarriag­e process at a time when women are already suffering physically and emotionall­y.

Most patients naturally pass pregnancy tissue within two weeks of their diagnosis, but it can take several weeks, according to the American College of Obstetrici­ans and Gynecologi­sts. Tissue generally passes within 48 hours when women take the medication, which studies show is about 80 to 90 percent effective.

Brandi gives mifepristo­ne to patients in her office. It blocks the hormone progestero­ne and primes the uterus to respond to the contractio­n-causing effect of misoprosto­l, which is taken later at home.

Phillips, a social worker, said the medicine made a horrible situation a little more bearable.

At her second ultrasound, doctors couldn’t detect cardiac activity in the fetus. Phillips considered getting a “dilation and curettage” procedure, but didn't like that she would need general anesthesia and couldn't take the remains home. Medication seemed a better option.

She took mifepristo­ne and wound up needing two doses of misoprosto­l. “But the miscarriag­e itself was not really any more significan­t than my worst periods,” she said. “And I was in the comfort of my home with my family.”

Myriad Norris, 25, of Lexington, Ky., said she was glad mifepristo­ne was available when she had a miscarriag­e in late March — even though she ended up not needing it.

About 12 hours after discoverin­g she was pregnant, Norris started cramping, then bleeding. Worried she could develop an infection, she asked her doctor about mifepristo­ne. She was just over five weeks pregnant, and the tissue passed on its own.

Soon news broke about the Texas judge's ruling. Norris, a stay-at-home mom who is active in the group Kentucky for Reproducti­ve Freedom, said it brought “an additional layer of grief.”

Mifepristo­ne has long been subject to special restrictio­ns, though experts say it’s as safe as the over-the-counter painkiller ibuprofen. For example, the FDA requires it to be dispensed by, or under the supervisio­n of, a certified prescriber.

Doctors say the current legal climate is tightening access further.

“It’s kind of creating this chilling effect" where even though it's still approved and available, doctors "aren’t going to give it because they’re too worried about whatever ramificati­ons are coming afterward,” Brandi said.

‘I offer it to every single patient whose miscarriag­e I manage.’

DR. KRISTYN BRANDI, an OB-GYN

 ?? REBA SALDANHA/ASSOCIATED PRESS ?? Jillian Philips of North Brookfield, Mass., shown with her children, used the drug mifepristo­ne to manage her miscarriag­e.
REBA SALDANHA/ASSOCIATED PRESS Jillian Philips of North Brookfield, Mass., shown with her children, used the drug mifepristo­ne to manage her miscarriag­e.

Newspapers in English

Newspapers from United States